Not a good buy right now for an impatient investor: the tape is still bearish (negative/expanding MACD) and there are no Intellectia buy signals to lean on.
The biggest near-term red flag is behavior from insiders: selling activity surged (+1947.69% last month), which works against a “buy it now” decision.
Options positioning is very call-heavy (put/call OI ratio 0.12), but actual trading volume is thin today; I’d treat it as weak confirmation rather than a reliable bullish tell.
The next clear catalyst is QDEC 2025 earnings (2026-02-16 after hours). Without a positive catalyst in the tape/news this week, odds favor chop/down before a sustained move.
No recent congress trading data and no noted politician/influential-figure transactions in the provided data.
Technical Analysis
Trend/Momentum: MACD histogram is negative (-0.047) and expanding lower, signaling downside momentum is strengthening.
RSI: RSI(6) at ~25.85 is effectively oversold, which can support a short-term bounce, but it’s not a trend reversal signal on its own.
Moving averages: Converging MAs suggest consolidation, but with bearish momentum it’s more consistent with a weak base than a confirmed turn.
Levels: Pivot 2.278 is overhead resistance; price (1.975) is below pivot.
Near support: S1 2.024 (already below), then S2 1.867 as the next key downside level.
Upside resistance zones: R1 2.532, R2 2.689.
Practical read: Until price reclaims ~2.28 (pivot) and MACD stops deteriorating, the higher-probability trade is “avoid/hold,” not “buy now.”
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning/Sentiment: Open interest is call-dominant (Call OI 8,633 vs Put OI 1,075; OI put/call 0.12) → bullish skew from existing positioning.
Activity today: Total volume is light (50 calls, 0 puts; volume put/call 0.0). This makes the bullish skew less convincing as a fresh sentiment signal.
Volatility: 30D IV ~71.1% vs historical vol ~65.0%; IV percentile 18.73 and IV rank 5.81 → IV is relatively low vs its own history (options not “panic-priced”).
Interpretation: Skew leans bullish, but the lack of put volume and overall low volume reduces confidence; not enough to override bearish technicals + insider selling.
can fuel a quick technical bounce if buyers step in near S2 (~1.
or on a reclaim of ~2.
Upcoming event: QDEC 2025 earnings on 2026-02-16 (after hours) can re-rate the stock quickly if cash burn/catalyst timeline is better than feared.
Neutral/Negative Catalysts
can pressure shares if burn rate/guidance disappoints.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: 0 (0.00% YoY) — no operating revenue showing in the snapshot.
Net income: -$21.715M, down 23.39% YoY (loss widened).
EPS: -0.29, down 25.64% YoY (worsened).
Takeaway: Financial trend is deteriorating YoY on profitability metrics, which reduces the appeal of buying ahead of catalysts unless momentum/signals improve.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent action: (2025-11-11) Stifel lowered price target to $11 from $12 and maintained a Buy rating.
Trend summary: Rating stayed positive (no downgrade), but the price target was trimmed slightly.
Wall Street pros: Maintained Buy suggests confidence in the longer-term program/data thesis; PT implies substantial upside vs ~$1.98 if execution/catalysts land.
Wall Street cons: PT cut and commentary highlight uncertainty/timing around data disclosure; near-term visibility remains a concern.
Wall Street analysts forecast NKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NKTX is 12.33 USD with a low forecast of 10 USD and a high forecast of 16 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast NKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NKTX is 12.33 USD with a low forecast of 10 USD and a high forecast of 16 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.920
Low
10
Averages
12.33
High
16
Current: 1.920
Low
10
Averages
12.33
High
16
Stifel
Buy
downgrade
$12 -> $11
AI Analysis
2025-11-11
Reason
Stifel
Price Target
$12 -> $11
AI Analysis
2025-11-11
downgrade
Buy
Reason
Stifel lowered the firm's price target on Nkarta to $11 from $12 and keeps a Buy rating on the shares. The firm believes management's decision to forego a preliminary year-end 2025 data disclosure and instead guide to the presentation of a more-fulsome data set at a FY26 medical conference should remove a near-term overhang given the former disclosure format was perceived to be mostly inconclusive, the analyst tells investors following the Q3 update.
Stifel
Stephen Willey
Buy
downgrade
$14 -> $12
2025-08-14
Reason
Stifel
Stephen Willey
Price Target
$14 -> $12
2025-08-14
downgrade
Buy
Reason
Stifel analyst Stephen Willey lowered the firm's price target on Nkarta to $12 from $14 and keeps a Buy rating on the shares. The recent earnings announcement and corporate update did not provide "any incremental surprises" as management is still guiding to the disclosure of preliminary data from the Ntrust-1/2 trials evaluating NKX019 in autoimmune disease before year-end, the analyst tells investors. The firm's reduced price target mostly reflects revised longer-term financing assumptions and valuation, the analyst noted.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NKTX
